This page contains a Flash digital edition of a book.
LAW CHANGES


by the United States Patent and Trademark Office (USPTO). Te FDA’s review of the proposed drug name focuses on whether a proposed trademark is likely to be confused by pharmacists and health professionals with other pharmaceutical trademarks. Te FDA recently launched a two- year pilot programme to enable pharmaceutical firms to evaluate their own names and to submit the data from the evaluation to the FDA for review. Tis does not circumvent the usual FDA trademark review procedures, but the pilot is intended to assist the FDA in determining whether it offers a better model than the current de novo FDA review.


Te changes that have been highlighted illustrate the constant adjustments


to IP laws and life


sciences regulation around the world. Te regulatory chessboard is in perpetual flux as governments and industry players continually move the pieces. It is hard to keep up so as to take advantage of the latest developments or to have some prior notice of adverse changes. Te only effective strategy is to stay tuned, look ahead and respond nimbly as the game shiſts.


Te following members of the Baker & McKenzie global IP practice group made contributions for their respective jurisdictions: managing contributor Richard Gough (Australia); Jane


Woodhouse (Australia); Bill Richardson (Canada); Ken Nakayama (Japan); Grace Shao (Taiwan); Say Sujintaya and Dhiraphol Suwanprateep (Tailand); Isabella Liu (China); Ewa Rutkowska (Poland): Rebecca Lederhouse (US); Dianne Phoebus (Venezuela). For more information, visit www.bakermckenzie.com/intellectualproperty


Richard Gough is a partner in the Sydney office of Baker & McKenzie where he specialises in intellectual property law. He handles patent, trade secrets, trademark and copyright litigation, disputes and enforcement, and provides related counsel, including to life sciences companies. Gough has been listed as one of Australia’s ‘Best Lawyers’ from 2008 to 2011 and as a ‘Key Individual for IP’ in Chambers Global 2011. He is a member of the editorial panel of World Intellectual Property Review.


Jane Woodhouse is an associate in the Sydney office of Baker & McKenzie, where she advises on intellectual property law. She was admitted to the Australia Bar in 2006 and joined the firm in 2008. Woodhouse is a science graduate who represents clients in the life sciences and other sectors in IP advisory and dispute-related matters.


www.worldipreview.com


Life Sciences Intellectual Property Review 2011


17


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84